Champions Oncology, Inc. financial data

Symbol
CSBR on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
855 N. Wolfe Street, Suite 619, Baltimore, MD
State of incorporation
DE
Fiscal year end
April 30
Former names
CHAMPIONS BIOTECHNOLOGY, INC. (to 3/30/2011), CHAMPIONS SPORTS INC (to 2/16/2007)
Latest financial report
10-Q - Q3 2024 - Dec 16, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 66.4 % -19.1%
Debt-to-equity -2.95K % -452%
Return On Equity 68.9 %
Return On Assets -2.41 % +92%
Operating Margin -1.47 % +92.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 13.8M shares +1.66%
Common Stock, Shares, Outstanding 13.7M shares +0.77%
Entity Public Float 22M USD -21.4%
Common Stock, Value, Issued 14K USD 0%
Weighted Average Number of Shares Outstanding, Basic 13.6M shares +0.72%
Weighted Average Number of Shares Outstanding, Diluted 14M shares +3.85%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 53.6M USD +7.19%
Research and Development Expense 7.38M USD -35.1%
Selling and Marketing Expense 7M USD -1.38%
General and Administrative Expense 9.94M USD -8.4%
Operating Income (Loss) -788K USD +91.7%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -637K USD +93.3%
Income Tax Expense (Benefit) -39K USD -151%
Net Income (Loss) Attributable to Parent -622K USD +93.5%
Earnings Per Share, Basic -0.05 USD/shares +93%
Earnings Per Share, Diluted -0.06 USD/shares +91.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 2.75M USD -50%
Accounts Receivable, after Allowance for Credit Loss, Current 10.5M USD +36%
Assets, Current 14.1M USD +0.48%
Property, Plant and Equipment, Net 7.71M USD +10.4%
Operating Lease, Right-of-Use Asset 5.67M USD -16.8%
Goodwill 335K USD 0%
Other Assets, Noncurrent 185K USD 0%
Assets 25.2M USD -10.8%
Accounts Payable, Current 4.85M USD +7.01%
Accrued Liabilities, Current 2.24M USD +10.5%
Contract with Customer, Liability, Current 10.2M USD -21.4%
Liabilities, Current 18.9M USD -9.97%
Operating Lease, Liability, Noncurrent 5.37M USD -20.7%
Other Liabilities, Noncurrent 324K USD -31.9%
Liabilities 24.6M USD -12.9%
Retained Earnings (Accumulated Deficit) -82.6M USD -0.73%
Stockholders' Equity Attributable to Parent 681K USD +632%
Liabilities and Equity 25.2M USD -10.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 311K USD
Net Cash Provided by (Used in) Financing Activities -37K USD +93.7%
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 13.8M shares +0.77%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 274K USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 2.75M USD -50%
Deferred Tax Assets, Valuation Allowance 18.1M USD +8.06%
Deferred Tax Assets, Gross 18.1M USD +8.06%
Operating Lease, Liability 6.78M USD -15.8%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Lessee, Operating Lease, Liability, to be Paid 12.6M USD -18.6%
Property, Plant and Equipment, Gross 16.2M USD -1.41%
Operating Lease, Liability, Current 1.4M USD +9.88%
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.92M USD -1.15%
Lessee, Operating Lease, Liability, to be Paid, Year One 2.95M USD +1.65%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 5.81M USD -21.6%
Lessee, Operating Lease, Liability, to be Paid, Year Three 2.87M USD -1.68%
Deferred Tax Assets, Operating Loss Carryforwards 9.04M USD -7.36%
Unrecognized Tax Benefits 181K USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 2.39M USD -16.6%
Depreciation, Depletion and Amortization 1.62M USD -16.6%
Share-based Payment Arrangement, Expense 909K USD -10.4%